- New four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)
- Roche Annual General Meeting 2023
- Assemblée générale 2023 de Roche
- Roche Generalversammlung 2023
- FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
- Roche launches two new antibodies to identify key clinical mutations in patients with brain cancer
- [Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
- [Ad hoc-Mitteilung gemäss Art. 53 KR] Transaktion in Roche Inhaberaktien
- New phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
- Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 245.85 |
Average volume | -- |
---|---|
Shares outstanding | 809.25m |
Free float | 721.97m |
P/E (TTM) | 17.04 |
Market cap | 214.03bn CHF |
EPS (TTM) | 15.36 CHF |
Annual div (ADY) | 9.64 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 16 2023 |
Div pay-date | Mar 20 2023 |
Data delayed at least 15 minutes, as of Jun 28 2019 07:11 BST.
More ▼